Wardwizard Foods and Beverages Limited reported a significant 96.4% drop in revenue to Rs 2.40 crore for the September 2026 quarter, swinging from a profit to a net loss of Rs 2.38 crore. The board also announced the appointment of two new independent directors.
Wardwizard Foods Posts Sharp Q2 Decline
Revenue fell to Rs 2.40 crore from Rs 67.44 crore year-over-year. Net loss reached Rs 2.38 crore compared to a profit of Rs 0.58 crore in Q2 2025.
Reader Takeaway: Dramatic revenue contraction and shift to loss present significant operational challenges for the company's growth outlook.
What just happened
Wardwizard Foods and Beverages Limited has disclosed its financial performance for the quarter ended September 30, 2026. The results indicate a substantial cooling in business activity, with top-line revenue plunging 96.4% compared to the same period last year. Consequently, the company swung from a net profit of Rs 0.58 crore to a net loss of Rs 2.38 crore.
Board and Governance Update
Alongside the financial results, the company’s Board of Directors approved the induction of two new Additional Non-Executive Independent Directors: Mr. Bhavin Rajubhai Patel and Mr. Vishal Manharbhai Shah. Both appointments are effective from November 04, 2026, for a five-year term, subject to shareholder approval at the upcoming General Meeting. The company confirmed that neither director has been debarred by SEBI or any other regulatory authority.
Why this matters
The sharp decline in revenue raises questions regarding the company's current business model and market demand for its products. While board additions are often intended to strengthen governance, investors are likely to prioritize explanations regarding the massive drop in sales volume and the shift to negative margins.
What to track next
Shareholders should look for official management commentary regarding the specific drivers behind the revenue collapse. Monitoring the company's cost-control initiatives and future operational strategies will be essential to gauge the trajectory of the firm's recovery in the upcoming quarters.
